Anti-KMT2A Polyclonal Antibody (KO Validated) for WB and ELISA - Q03164

Core Product Specifications and Parameters

Biological Background: KMT2A Function and Localization

• Histone-lysine N-methyltransferase 2A (KMT2A), also known as MLL, HRX, or ALL-1, is a member of the Trithorax family of chromatin regulators. It plays an essential role in early development and hematopoiesis through histone H3K4 methylation (PubMed:12453419, PubMed:15960975, PubMed:19187761). Related references: PMID:12453419 PMID:15960975 PMID:19187761
• KMT2A is the catalytic subunit of the MLL1/MLL complex, which mediates both H3K4 methylation and H4K16 acetylation, thereby regulating chromatin accessibility at active gene promoters.
• It binds unmethylated CpG elements in promoter regions and helps maintain their nonmethylated state. This activity is required for transcriptional activation of target genes such as HOXA9 (PubMed:20010842, PubMed:20677832). Related references: PMID:20010842 PMID:20677832
• KMT2A promotes PPP1R15A-induced apoptosis, highlighting a role in programmed cell death (PubMed:10490642). Related references: PMID:10490642
• In the circadian clock, KMT2A establishes a permissive chromatin state through rhythmic H3K4 methylation, which facilitates CLOCK-BMAL1 recruitment and circadian gene expression (By similarity).
• The protein exhibits auto-methylation activity on cysteine 3882 in the absence of histone substrates (PubMed:24235145). Related references: PMID:24235145
• KMT2A is predominantly localized in the nucleus and is expressed in heart, lung, brain, and T- and B-lymphocytes. It is classified as a proto-oncogene and is frequently involved in chromosomal rearrangements associated with acute leukemias.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 752–949 of human KMT2A, located in the N-terminal region. This antibody may detect full-length KMT2A as well as N-terminal fragments or fusion proteins derived from chromosomal translocations, making it potentially useful for studying MLL-rearranged leukemias.
• Due to the large molecular weight of KMT2A (~432 kDa), consider using low-percentage SDS-PAGE gels (e.g., 6–8%) and extended wet transfer times (>4 hours at 30 V) for western blotting. Coomassie staining of the gel after transfer can help confirm efficient protein migration.
• For western blot, validate the antibody in knockout (KO) cell lines or tissue samples to confirm specificity, as indicated by the KO validation status. Include appropriate positive and negative controls.
• In ELISA applications, the polyclonal nature of the antibody provides broad epitope coverage but may require careful blocking and washing optimization to reduce background.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers and research institutions streamlined access to IVD raw materials, including validated primary antibodies, antibody pairs, and ancillary reagents. The KMT2A polyclonal antibody supports epigenetics and leukemia research, and CamelBio’s supply chain can accommodate bulk orders, custom buffer formulations, and rare-target sourcing to accelerate your IVD development projects.